Clinical Trials Nct Page

Summary
EudraCT Number:2021-005551-36
Sponsor's Protocol Code Number:NL79416.018.21
National Competent Authority:Denmark - DHMA
Clinical Trial Type:EEA CTA
Trial Status:Trial now transitioned
Date on which this record was first entered in the EudraCT database:2023-02-28
Trial results
A. Protocol Information
A.1Member State ConcernedDenmark - DHMA
A.2EudraCT number2021-005551-36
A.3Full title of the trial
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized Trial
A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
Outcomes for people with cardiogenic shock after myocardial infarction by comparing two blood pressure targets.
A.3.2Name or abbreviated title of the trial where available
NORSHOCK
A.4.1Sponsor's protocol code numberNL79416.018.21
A.7Trial is part of a Paediatric Investigation Plan No
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorAmsterdam University Medical Center, AMC
B.1.3.4CountryNetherlands
B.3.1 and B.3.2Status of the sponsorNon-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing supportZonMW
B.4.2CountryNetherlands
B.4.1Name of organisation providing supportAMC Medical Research
B.4.2CountryNetherlands
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisationAMC
B.5.2Functional name of contact pointProf Henriques
B.5.3 Address:
B.5.3.1Street AddressMeibergdreef 9
B.5.3.2Town/ cityAmsterdam
B.5.3.3Post code1105 AZ
B.5.3.4CountryNetherlands
B.5.4Telephone number+31205669111
B.5.6E-mailj.p.henriques@amsterdamumc.nl
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation Yes
D.2.1.1.1Trade name Norepinephrine
D.2.1.1.2Name of the Marketing Authorisation holderHospira UK Limited
D.2.1.2Country which granted the Marketing AuthorisationNetherlands
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.4Pharmaceutical form
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPIntravascular use (Noncurrent)
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNNorepinephrine
D.3.9.1CAS number 51-41-2
D.3.9.4EV Substance CodeSUB09360MIG
D.3.10 Strength
D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
D.3.10.2Concentration typerange
D.3.10.3Concentration number0.1 to 1.0
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin Yes
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product No
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product No
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Myocardial infarction related cardiogenic shock
E.1.1.1Medical condition in easily understood language
Cardiogenic shock after myocardial infarction
E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
MedDRA Classification
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
To investigate whether outcomes for patients with cardiogenic shock is better (in terms of survival and renal functioning) when less norepinephrine is administered.
E.2.2Secondary objectives of the trial
To evaluate cost-effectiveness.
E.2.3Trial contains a sub-study No
E.3Principal inclusion criteria
1. Acute myocardial infarction, STEMI or NSTEMI
2. Early revascularization by PCI
3. Cardiogenic shock, characterized by:
I. Signs of impaired organ perfusion with at least one of the following criteria:
a. Altered mental status
b. Cold, clammy skin and extremities
c. Oliguria with urine output < 30ml/hour
d. Serum lactate > 2.0 mmol/L
II. a. Systolic blood pressure (SBP) < 90 mmHg for > 30 minutes, OR
b. Use of drugs to maintain SBP > 90 mmHg at presentation before randomization.
III. Clinical signs of pulmonary congestion
E.4Principal exclusion criteria
-Resuscitation > 30 minutes
- Mechanical cause of cardiogenic shock (e.g. papillary muscle rupture, ventricular septal rupture)
- Onset of shock > 12 hours
- Imminent need for mechanical circulatory support
-Women < 45 years
E.5 End points
E.5.1Primary end point(s)
The composite of all-cause mortality and severe renal failure requiring renal replacement therapy within 30 days after randomization.
E.5.1.1Timepoint(s) of evaluation of this end point
30 days after randomization
E.5.2Secondary end point(s)
All-cause mortality at 30 days
Days alive and out of hospital (30 days)
Days alive and out of ICU (30 days)
Cardiovascular death at 1 year
Enzymatic infarct size
Lactate clearance (mean + area under the curve 0-36 hours)
Days alive and free of mechanical ventilation (30 days)
Days alive and free of mechanical circulatory support (30 days)
Severe renal failure requiring renal replacement therapy (at 30 days, 1 year)
Renal function (during hospital stay and 1 year)
Time to peak creatinine (hospital stay)
Time to renal replacement therapy
Days alive and free of catecholamine therapy (30 days)
Vasoactive inotropic score (VIS) (during hospital stay)
Time to hemodynamic stabilization (hospital stay)
Blood pressure and heart rate during the first 24 hours
Hemodynamic parameters (during ICU / CCU admission)
Arrhythmias during hospital admission
Major vascular complication during hospital admission
Infection / sepsis during hospital admission
Myocardial re-infarction within 30 days
Left ventricular ejection fraction (at day 3, before hospital discharge, and at 1 year)
Neurological outcome (at 30 days and 1 year)
Protocol adherence / use of bail-out therapy
Hospital readmission for cardiac reason within 1 year
E.5.2.1Timepoint(s) of evaluation of this end point
30 days, 1 year
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis No
E.6.3Therapy Yes
E.6.4Safety No
E.6.5Efficacy No
E.6.6Pharmacokinetic No
E.6.7Pharmacodynamic No
E.6.8Bioequivalence No
E.6.9Dose response No
E.6.10Pharmacogenetic No
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others No
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) No
E.7.3Therapeutic confirmatory (Phase III) No
E.7.4Therapeutic use (Phase IV) Yes
E.8 Design of the trial
E.8.1Controlled Yes
E.8.1.1Randomised Yes
E.8.1.2Open Yes
E.8.1.3Single blind No
E.8.1.4Double blind No
E.8.1.5Parallel group No
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) No
E.8.2.2Placebo No
E.8.2.3Other Yes
E.8.2.3.1Comparator description
Lower dose of norepinehprine
E.8.2.4Number of treatment arms in the trial2
E.8.3 The trial involves single site in the Member State concerned No
E.8.4 The trial involves multiple sites in the Member State concerned Yes
E.8.4.1Number of sites anticipated in Member State concerned2
E.8.5The trial involves multiple Member States Yes
E.8.5.1Number of sites anticipated in the EEA11
E.8.6 Trial involving sites outside the EEA
E.8.6.1Trial being conducted both within and outside the EEA No
E.8.6.2Trial being conducted completely outside of the EEA No
E.8.7Trial has a data monitoring committee Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
LVLS
E.8.9 Initial estimate of the duration of the trial
E.8.9.1In the Member State concerned years4
E.8.9.1In the Member State concerned months0
E.8.9.1In the Member State concerned days0
E.8.9.2In all countries concerned by the trial years4
E.8.9.2In all countries concerned by the trial months0
E.8.9.2In all countries concerned by the trial days0
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 No
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) No
F.1.1.5Children (2-11years) No
F.1.1.6Adolescents (12-17 years) No
F.1.2Adults (18-64 years) Yes
F.1.2.1Number of subjects for this age range: 276
F.1.3Elderly (>=65 years) Yes
F.1.3.1Number of subjects for this age range: 500
F.2 Gender
F.2.1Female Yes
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers No
F.3.2Patients Yes
F.3.3Specific vulnerable populations Yes
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception No
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation Yes
F.3.3.6Subjects incapable of giving consent personally Yes
F.3.3.6.1Details of subjects incapable of giving consent
Patients in cardiogenic shock are by definition incapacitated.
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.1In the member state100
F.4.2 For a multinational trial
F.4.2.1In the EEA 776
F.4.2.2In the whole clinical trial 776
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
None
G. Investigator Networks to be involved in the Trial
N. Review by the Competent Authority or Ethics Committee in the country concerned
N.Competent Authority Decision Authorised
N.Date of Competent Authority Decision2023-05-01
N.Ethics Committee Opinion of the trial applicationFavourable
N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.Date of Ethics Committee Opinion2023-04-12
P. End of Trial
P.End of Trial StatusTrial now transitioned
3